Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praliciguat in Heart Failure With Preserved Ejection Fraction (CAPACITY-HFpEF)
NCT03254485Phase 2Completed
- Sponsor
- Akebia Therapeutics
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of praliciguat in heart failure with preserved ejection fraction (HFpEF), sponsored by Akebia Therapeutics. Started Nov 2017; status: completed.
02
Drugs
praliciguat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03254485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254485.